Goldman Sachs analyst Scott Fidel lowered the firm’s price target on Ardent Health (ARDT) to $12 from $19 and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $17 from $21 at Stephens
- Cautious Hold on Ardent Health Partners Amidst Guidance Cuts and Competitive Disadvantages
- Ardent Health downgraded to Equal Weight from Overweight at Morgan Stanley
- Ardent Health Reports Q3 2025 Financial Results
- Ardent Health Partners Reports Strong Q3 Amid Cost Challenges